Affimed N.V. (Affimed) is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s research and development pipeline consists of AFM13, AFM11, AFM21, TandAb and Trispecific Ab. The Company’s lead candidate, AFM13, is a NK-cell TandAb designed for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin Lymphoma, or HL. AFM11 is a T-cell TandAb designed for the treatment of certain CD19+ B-cell malignancies, including non-Hodgkin Lymphoma, or NHL, Acute Lymphocytic Leukemia, or ALL, and Chronic Lymphocytic Leukemia, or CLL. AFM21 selectively binds Epidermal Growth Factor Receptor variant III, or EGFRvIII. The Company’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.
